Hormonal
GLP-1 analogues (Semaglutide and Liraglutide) are recommended for MASLD patients with BMI >27 kg/m2 and CVD risk factors when lifestyle intervention is insufficient, offering significant weight loss and CVD risk reduction.
If lifestyle changes alone haven't reduced your weight or CVD risk, and your BMI is above 27, ask your doctor about GLP-1 analogues like Semaglutide or Liraglutide. These medications can help you lose significant weight (up to 15% with Semaglutide) and improve your heart health.
Semaglutide (2.4 mg/weekly) seems to induce a more robust weight loss of 15 % after 68 weeks... Liraglutide (3.0 mg daily) induced weight loss of up to 5–6% after 56 weeks... GLP-1 analogues should be considered in MALSD patients with a BMI above 27 kg/m2 and CVD risk factors when lifestyle intervention has not been sufficient.
Why this rating
Based on approved indications for T2DM/obesity and promising but ongoing long-term phase 3 trials for MASLD/CVD specific outcomes.
Source
Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease
Anders Mellemkjær et al. · European Journal of Internal Medicine · 2023
DOI 10.1016/j.ejim.2023.11.012
More from this paper
- Lifestyle interventions, specifically a Mediterranean diet and 150-300 minutes of moderate or 75-150 minutes of vigorous exercise weekly, are recommended to induce weight loss and improve cardiovascular risk factors in patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).Good
- Statins are safe and effective as first-line treatment for hyperlipidemia in MASLD patients, despite under-prescription, and may reduce cardiovascular events and liver disease burden.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →